Abstract

Some studies suggest an association between diabetic kidney disease (DKD) and vitamin D (VD), but there is no data about the effect of high dose of VD on DKD in type 1 diabetes mellitus (T1DM). Our pilot study aims to evaluate albuminuria reduction in patients with T1DM supplemented with high dose of VD. 22 patients received doses of 4,000 and 10,000 IU/day of cholecalciferol for 12 weeks according to patient's previous VD levels. They were submitted to continuous glucose monitoring system, 24 hours ambulatory blood pressure monitoring and urine albumin-to-creatinine ratio before and after VD supplementation. There was a reduction of DKD prevalence at the end of the study (68 vs 32%; p = 0.05), with no changes on insulin doses, glycated hemoglobin, glycemic variability and blood pressure values. A correlation between percentage variation of VD levels (ΔVD) and albuminuria at the end of the study was presented (r = -0.5; p < 0.05). Among T1DM patients with DKD at the beginning of the study, 8/13 (62%) had their DKD stage improved, while the other five ones (38%) showed no changes (p < 0.05). Our pilot study suggests an association between VD high dose supplementation, lower prevalence and improvement in stages of DKD in T1DM.

Highlights

  • It is well known that better glycemic, blood pressure (BP) control and angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) are useful tools in early stages of diabetic kidney disease (DKD)

  • Our pilot study aims to evaluate possible albuminuria reduction in patients with type 1 diabetes mellitus (T1DM) and DKD, supplemented with high dose of vitamin D (VD)

  • Our pilot study suggests an association between VD supplementation and an improvement in DKD stages on patients with T1DM

Read more

Summary

Introduction

It is well known that better glycemic, blood pressure (BP) control and angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) are useful tools in early stages of diabetic kidney disease (DKD). Even though it remains an important cause of mortality in type 1 diabetes mellitus (T1DM) patients [1], vitamin D (VD) acts on renin–angiotensin system, inflammatory cascade, and vasculature [2, 3]. Our pilot study aims to evaluate albuminuria reduction in patients with T1DM supplemented with high dose of VD

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call